Brief: Insilico Medicine Cayman Topco Receives Center For Drug Evaluation's IND Approval For Inhaled Rentosertib
29/04/2026 02:36
April 29 (Reuters) - Insilico Medicine Cayman TopCo 3696.HK: RECEIVES CENTER FOR DRUG EVALUATION OF NMPA'S IND APPROVAL FOR INHALED RENTOSERTIB Further company coverage: 3696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insilico Medicine Cayman TopCo
See all newsInSilico Medicine jumps on progress in testing of new weight-loss drug
Development Collaboration
InSilico jumps on collaboration to develop biological frontier foundation models
HK-listed InSilico Medicine climbs as chairman buys shares
Brief: Insilico Medicine Cayman Topco's Chair Purchases Aggregate 113,500 Shares In Sept 4-7